Animal testing - Articles - Page 2

FDA wants a shift away from animal testing

April 11, 2025

In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower costs for companies and patients. It’s another step in a process of changing rules put in place decades ago.

Senators send stern message to US FDA on animal testing

Sep. 16, 2024

By Mari Serebrov

While it’s called the FDA Modernization Act (FDAMA) 3.0, the short bipartisan bill introduced in the U.S. Senate Sept. 15 is basically a message to the FDA: “The move away from animal testing in FDAMA 2.0 wasn’t a congressional suggestion. It’s a mandate, so get it done.”

Drug Design, Drug Delivery & Technologies

Consortium to research alternatives to animal testing

Feb. 2, 2024

The European Chemicals Agency (ECHA) has contracted a consortium to conduct scientific studies on the reliability and relevance of new approach methodologies (NAMs) as alternatives to animal testing and to promote the use of such methods in the future.

Drug design, drug delivery & technologies

US spending bill spares animals in preclinical drug development

Dec. 30, 2022

By Mari Serebrov

Tucked into the 4,155-page, $1.7 trillion spending bill for fiscal 2023 that U.S. President Joe Biden signed into law Dec. 23 is a small provision that may have outsized impact on future biosimilar and other drug development. Championed by lawmakers on both sides of the political spectrum, the provision modernizes the data that can be used to support drug development, including alternatives to animal studies.

US spending bill spares animals in preclinical drug development

Dec. 29, 2022

By Mari Serebrov

Tucked into the 4,155-page, $1.7 trillion spending bill for fiscal 2023 that U.S. President Joe Biden signed into law Dec. 23 is a small provision that may have outsized impact on future biosimilar and other drug development. Championed by lawmakers on both sides of the political spectrum, the provision modernizes the data that can be used to support drug development, including alternatives to animal studies.

One small step for biopharma could be giant leap for animalkind

April 4, 2022

By Mari Serebrov

Four biopharma companies are pooling some of their chemical data and making it public for the first time as part of the pioneering stage of a European effort to reduce the need for animal testing in drug development.

New EMA measures aimed at reducing use of animals in drug development

Sep. 30, 2021

The EMA is taking another step in its efforts to reduce animal testing in drug development.

Hesperos' 'human-on-a-chip' in vitro system predicts in vivo results for multiple drugs

July 10, 2019

By Annette Boyle

Hesperos Inc.'s human-on-a-chip in vitro model for the first time successfully predicted human response to two drugs. The multi-organ model provided new insight into the drugs' cardiotoxic effects in a study published in Nature Scientific Reports. The Orlando, Fla.-based company also recently demonstrated that its model could simultaneously measure cancer drug efficacy and off-target toxicity without animal models or human testing.